“`html
Core News Facts
Pfizer (NYSE: PFE) has seen its shares decline by 50% since December 2022, primarily due to falling revenues from its COVID-19 treatments, Comirnaty and Paxlovid, which together accounted for over 54% of its $100.3 billion revenue in 2022. In Q3 2025, Paxlovid revenue decreased by 55% year-over-year, while Comirnaty revenue fell by 20%. A looming patent cliff, including the expiration of its pneumococcal vaccine Prevnar 13 patent in 2026 and other patents in 2027, is expected to affect $236 billion in worldwide revenue for pharmaceuticals by 2030.
In an effort to revitalize its pipeline, Pfizer acquired biotech startup Metsera for approximately $10 billion on November 7, 2025, potentially entering the $133 billion weight loss drug market. Metsera’s MET-097i obesity drug has shown promising results in trials and could yield peak sales of $5 billion annually. Pfizer is also advancing AI in drug discovery, already saving $7.7 billion in anticipated overall savings while investing $500 million into R&D, aiming to leverage digital infrastructure for efficient drug development.
“`
